Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characteristics of Strokes in Down Syndrome Patients, A single center decade experience
Cerebrovascular Disease and Interventional Neurology
P6 - Poster Session 6 (5:30 PM-6:30 PM)
13-008

With advances in modern medicine, life expectancy of patients with Down syndrome has reached about 60 years of age.  While noteworthy, this does come with increased risks of medical complications, specifically including increased stroke risk. Causes of stroke in Down syndrome are multiple; in addition to common stroke etiologies, these include:  moyamoya, congenital heart disease, atlanto axial subluxation (predisposing to arterial dissection), hypothyroidism associated hyperlipidemia, hematologic malignancies and their treatments., and cardiovascular complications of obstructive sleep apnea.

Down syndrome is commonly associated with heterogeneous groups of disorders that may result in arterial or venous stroke. We sought to explore our experience at Loyola (LUHS) and describe some of the risk factors leading to stroke among patients with Down syndrome.

A retrospective chart analysis was conducted on Down syndrome patients at LUHS presenting with stroke from 01/01/2010 to 12/31/2021.  We recorded age, gender, race, ethnicity, stroke type and etiologies, medical comorbidities, intracranial location of stroke, NIHSS, modified Rankin (admission and discharge), interventions, hospital complications and disposition

We identified seven stroke patients with Down syndrome for whom full data was available. There were 5 ischemic strokes, 1 central venous sinus thrombosis, and 1 intracerebral hemorrhage. Cardiac abnormalities were the most common medical comorbidity. The 2 most frequent ischemic stroke etiologies were cardiovascular and moyamoya syndromes. Three patients did not survive their strokes,1 went to acute rehab and 3 were discharged home.

This study provides a perspective about  the ongoing complexity of Down syndrome stroke patients in the 21st century.   A comprehensive in-depth approach to explore stroke mechanisms and aggressive stroke risk factor modification of Downs Syndrome patients remains essential.

 
Authors/Disclosures
Anam Syed, DO (Rush University Medical Center)
PRESENTER
Dr. Syed has nothing to disclose.
Jasmine Singh, MD (Northwest Community Hospital) Dr. Singh has nothing to disclose.
Michael J. Schneck, MD, FAAN (Loyola University Chicago, Stritch School of Medicine) An immediate family member of Dr. Schneck has received personal compensation for serving as an employee of Cellcarta. Dr. Schneck has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for HLT Medical. Dr. Schneck has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Miscellaneous legal firms. Dr. Schneck has stock in Baxter Labs. The institution of Dr. Schneck has received research support from NIH.
Jose Biller, MD, FACP, FAHA, FAAN (Loyola University Stritch School of Medicine) Dr. Biller has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwer. Dr. Biller has received publishing royalties from a publication relating to health care.